These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21945959)

  • 1. The cost-effectiveness of rotavirus vaccination in Armenia.
    Jit M; Yuzbashyan R; Sahakyan G; Avagyan T; Mosina L
    Vaccine; 2011 Nov; 29(48):9104-11. PubMed ID: 21945959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia.
    De la Hoz F; Alvis N; Narváez J; Cediel N; Gamboa O; Velandia M
    Vaccine; 2010 May; 28(22):3856-64. PubMed ID: 20347057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
    Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
    Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam.
    Fischer TK; Anh DD; Antil L; Cat ND; Kilgore PE; Thiem VD; Rheingans R; Tho le H; Glass RI; Bresee JS
    J Infect Dis; 2005 Nov; 192(10):1720-6. PubMed ID: 16235169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination.
    Jit M; Edmunds WJ
    Vaccine; 2007 May; 25(20):3971-9. PubMed ID: 17400341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.
    Flem ET; Latipov R; Nurmatov ZS; Xue Y; Kasymbekova KT; Rheingans RD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S195-202. PubMed ID: 19817600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
    Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
    Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
    Tilson L; Jit M; Schmitz S; Walsh C; Garvey P; McKeown P; Barry M
    Vaccine; 2011 Oct; 29(43):7463-73. PubMed ID: 21821085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.
    Itzler RF; Chen PY; Lac C; El Khoury AC; Cook JR
    J Med Econ; 2011; 14(6):748-58. PubMed ID: 21919673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana.
    Abbott C; Tiede B; Armah G; Mahmoud A
    Vaccine; 2012 Mar; 30(15):2582-7. PubMed ID: 22321664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of childhood rotavirus vaccination in Taiwan.
    Wu CL; Yang YC; Huang LM; Chen KT
    Vaccine; 2009 Mar; 27(10):1492-9. PubMed ID: 19186200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries.
    Rheingans RD; Antil L; Dreibelbis R; Podewils LJ; Bresee JS; Parashar UD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S16-27. PubMed ID: 19817595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
    Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
    Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
    Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
    Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of a routine rotavirus vaccination programme in Indonesia.
    Wilopo SA; Kilgore P; Kosen S; Soenarto Y; Aminah S; Cahyono A; Ulfa M; Tholib A
    Vaccine; 2009 Nov; 27 Suppl 5():F67-74. PubMed ID: 19931723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe.
    Jit M; Bilcke J; Mangen MJ; Salo H; Melliez H; Edmunds WJ; Yazdan Y; Beutels P
    Vaccine; 2009 Oct; 27(44):6121-8. PubMed ID: 19715781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination.
    Shim E; Galvani AP
    Vaccine; 2009 Jun; 27(30):4025-30. PubMed ID: 19389452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries.
    Atherly D; Dreibelbis R; Parashar UD; Levin C; Wecker J; Rheingans RD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S28-38. PubMed ID: 19817610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of childhood rotavirus vaccination in Germany.
    Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
    Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand.
    Muangchana C; Riewpaiboon A; Jiamsiri S; Thamapornpilas P; Warinsatian P
    Vaccine; 2012 Apr; 30(18):2839-47. PubMed ID: 22387220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.